2022 Development Timelines
1AD - 2022 Goals
Significantprogress anticipated on both existing core programs and further pipelineexpansion
AD-214 – First in class anti-fibrotic
• Inhaledformulation development: nebulisation feasibility, efficacy in animal model ofIPF (Q1); lung distribution imaging in healthy and disease model animals (Q1);dose finding and clinical formulation (Q2)
• Intravenousformulation development (Q3)
• GLP toxicologywith inhaled formulation (commences 2H22)
• Continuing partneringdiscussions (Q1); selection of next indication
GE Healthcare – GZMB PET imaging
• Pre-clinicalproof of concept – milestone payment (mid-22)
Carina Biotech – i-body enabled CAR-T cells
• 1stexperimental results on Target #1
• Commencei-body discovery on Target #2
Internal pipeline and platform development
• Initialfunctional data on i-body binders against internal Target #2 (2H22)
• i-body2.0: newintellectual property filed (end’22)
• 7 programs inpipeline (end’22)
• Additionalpatent filings, grants on individual i-body enabled products
